Literature DB >> 8093746

Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis.

L C Miller1, E A Lynch, S Isa, J W Logan, C A Dinarello, A C Steere.   

Abstract

Borrelia burgdorferi, the causative agent of Lyme disease, is a potent inducer of interleukin-1 beta (IL-1 beta), a cytokine implicated in the pathogenesis of inflammatory arthritis. The balance between IL-1 and the IL-1 receptor antagonist (IL-1ra), a naturally occurring inhibitor of IL-1, might influence disease expression. To explore this possibility, we have done a retrospective study that compared the clinical course of Lyme arthritis in 83 patients with concentrations of IL-1 beta and IL-1ra in the patients' synovial fluid. Patients with high concentrations of IL-1ra and low concentrations of IL-1 beta had rapid resolution of attacks of arthritis, whereas patients with the reverse pattern of cytokine concentrations had long intervals to recovery. Thus, the balance between synovial fluid IL-1 beta and IL-1ra concentrations relates to the time to recovery from an episode of Lyme arthritis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093746     DOI: 10.1016/0140-6736(93)90006-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

Review 1.  Treatment of Lyme arthritis.

Authors:  M A Cimmino; G L Moggiana; M Parisi; S Accardo
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

2.  Macrophages and enriched populations of T lymphocytes interact synergistically for the induction of severe, destructive Lyme arthritis.

Authors:  B K DuChateau; J R Jensen; D M England; S M Callister; S D Lovrich; R F Schell
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental Shigellosis.

Authors:  J Arondel; M Singer; A Matsukawa; A Zychlinsky; P J Sansonetti
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.

Authors:  S B Cohen; L W Moreland; J J Cush; M W Greenwald; S Block; W J Shergy; P S Hanrahan; M M Kraishi; A Patel; G Sun; M B Bear
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

5.  Glomerular expression of interleukin-1 receptor antagonist and interleukin-1 beta genes in antibody-mediated glomerulonephritis.

Authors:  F W Tam; J Smith; S J Cashman; Y Wang; E M Thompson; A J Rees
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

6.  Fetal outcome in murine Lyme disease.

Authors:  R M Silver; L Yang; R A Daynes; D W Branch; C M Salafia; J J Weis
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Heritable susceptibility to severe Borrelia burgdorferi-induced arthritis is dominant and is associated with persistence of large numbers of spirochetes in tissues.

Authors:  L Yang; J H Weis; E Eichwald; C P Kolbert; D H Persing; J J Weis
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

8.  Polymorphisms of IL-6 174 G/C, IL-10 -592 C/A and risk of HIV/AIDS among North Indian population.

Authors:  Ranbir Chander Sobti; Nega Berhane; Salih Abdul Mahedi; Rupinder Kler; Seyed Ali Hosseini; Vijish Kuttiat; Ajay Wanchu
Journal:  Mol Cell Biochem       Date:  2010-04       Impact factor: 3.396

9.  Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease.

Authors:  J S Hyams; J E Fitzgerald; N Wyzga; W R Treem; C J Justinich; D L Kreutzer
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

Review 10.  Treatment of rheumatoid arthritis with IL-1 inhibitors.

Authors:  C Gabay; W P Arend
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.